Pregled bibliografske jedinice broj: 1070901
Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study
Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study // Pharmacogenomics journal, 20 (2020), 5; 638-646 doi:10.1038/s41397-020-0150-9 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1070901 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study
Autori
Bošnjak Kuharić, Dina ; Božina, Nada ; Ganoci, Lana ; Makarić, Porin ; Kekin, Ivana ; Prpić, Nikola ; Božina, Tamara ; Rojnić Kuzman, Martina
Izvornik
Pharmacogenomics journal (1470-269X) 20
(2020), 5;
638-646
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
schizophrenia and psychosis ; HSPA1B ; genetics ; psychopharmacogenetics
Sažetak
Our aim was to analyze the association of HSPA1B genotypes and treatment response measured by the changes of psychopathology and neurocognitive symptoms in patients with first- episode psychosis (FEP) after 18 months of treatment. A sample of 159 patients with FEP admitted at two Croatian psychiatric hospitals in the period between year 2014 and year 2017 was assessed at baseline and after 18 months of follow-up with Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS) and a battery of neurocognitive tests. Associations of scale and test results with HSPA1B polymorphic locus rs1061581 were analyzed using the general linear model. The carriers of the AA genotype showed the highest improvement in CDSS and RAVLT A test after the 18-month follow-up. Concordantly, we found significantly higher improvement assessed with the CDSS, RAVLT A, RAVLT A 30′ and positive PANSS scales in the not-GG (AA/AG) group compared with the GG group. Our study suggests that HSPA1B rs1061581variants may moderate treatment response in FEP measured with changes of psychopathology and neurocognitive test results.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
--UIP-2014-09-1245 - Biomarkeri u shizofreniji – integracija komplementarnih prisutupa u praćenju osoba s prvom psihotičnom epizodom (BIS – LF FEP) (Rojnić Kuzman, Martina) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče,
Klinički bolnički centar Zagreb
Profili:
Lana Ganoci
(autor)
Tamara Božina
(autor)
Nada Božina
(autor)
Martina Rojnić Kuzman
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE